Media Advisory: DoseMe Researchers to Present at IATDMCT-SFPT 2026 on Earlier Detection of Acute Kidney Injury Through Vancomycin Therapeutic Drug Monitoring
In this article:
New research will explore whether vancomycin TDM can identify kidney injury before changes in serum creatinine, highlighting the potential of bayesian dosing to support earlier clinical intervention
Tampa, FL – August 31, 2026
DoseMe, a leading provider of clinical decision support technologies, today announced Sophie Leech, PhD, Bioinformatician will present “Can vancomycin therapeutic drug monitoring detect acute kidney injury before serum creatinine?” at the IATDMCT-SFPT 2026 Congress in Rennes, France September 27 – 30.
This poster will cover new research examining whether vancomycin therapeutic drug monitoring (TDM) can detect acute kidney injury (AKI) before conventional changes in serum creatinine.
Using TDM data analyzed through DoseMeRx’s Bayesian dosing software, the research explores an important question in antimicrobial therapy: whether decreases in vancomycin clearance may provide an earlier signal of kidney injury, potentially giving clinicians additional information to support timely intervention.
The presentation underscores the growing role of therapeutic drug monitoring and model-informed precision dosing in helping clinicians optimize vancomycin therapy while managing the risk of nephrotoxicity. See the full agenda here: Program
WHO: Sophie Leech, PhD, will present and be available to discuss the research and broader implications for vancomycin dosing, therapeutic drug monitoring and precision dosing.
WHERE: ATRIUM, IATDMCT-SFPT 2026 Congress, Rennes, France
WHEN: Monday, September 28 – Tuesday, September 29, 2026
Additional Resources
About DoseMe
DoseMe is the provider of Firstline and DoseMeRx clinical decision support technologies that enable proactive, personalized care. Firstline is a mobile-first platform making treatment guidance accessible to every clinician, anywhere. DoseMeRx delivers clinically validated PK/PD models to individualize precision dosing in seconds. DoseMe’s evidence-based clinical intelligence helps reduce adverse drug events, antibiotic overuse, improved adherence to stewardship guidance, and provides clinicians a clear path to optimal care. For more information and real-world success stories, visit https://doseme-rx.com/success-stories